Compare Illumina, Inc. (ILMN) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nutanix Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Nutanix Inc trades at $54.8 (market cap $14.90B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | NTNX | |
|---|---|---|
Market Cap | $27.94B | $14.90B |
Sector | Health | Technology |
52-Week High | $194.33 | $81.12 |
52-Week Low | $91.00 | $34.41 |
Enterprise Value | $29.33B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Nutanix (NTNX) trades at $55.11, showing minimal daily change. The stock exhibits a bullish technical trend, supported by strong earnings beats in recent quarters, including Q1 2026 EPS of $0.47 versus $0.36 expected. Revenue growth is projected to increase from $2.54 billion in 2025 to $2.7 billion in 2026, with net income margin improving to 10.03%. Positive sentiment is fueled by recent news, such as the NVIDIA certification for its Unified Storage solution, highlighting its position in AI infrastructure.
The outlook for NTNX is positive, driven by consistent earnings outperformance and strategic positioning in hybrid multicloud and AI markets. Key opportunities include expanding profit margins and leveraging partnerships. Risks involve competitive pressures in cloud computing and reliance on enterprise spending. The consensus analyst price target of $57.80 suggests moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
